Fig. 1From: Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trialsPRISMA flow diagram of study screening and selectionBack to article page